Extracorporeal photopheresis did not prevent the development of an autoimmune disease: myasthenia gravis

Basit Öğe Kaydı
dc.authorid0000-0002-1407-2334
dc.contributor.authorUygun, Vedat
dc.contributor.authorDaloğlu, Hayriye
dc.contributor.authorIrmak Öztürkmen, Seda
dc.contributor.authorDöşemeci, Levent
dc.contributor.authorKarasu, Gülsün
dc.contributor.authorHazar, Volkan
dc.contributor.authorYeşilipek, Akif
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T20:03:20Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T20:03:20Z
dc.date.issued2016
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000390578300026
dc.descriptionPubMed ID: 27612294
dc.description.abstractBACKGROUNDMyasthenia gravis (MG) is a neuromuscular disorder characterized by an autoimmune defect in the neuromuscular junction. In most patients, the autoimmune attack is mediated by antibodies against the acetylcholine receptor (AChR) on the postsynaptic membrane. Deficient immunoregulation, including regulatory T cells, is consistently observed. Extracorporeal photopheresis (ECP) leads to the induction of regulatory T cells that mediate immunologic tolerance in autoimmune diseases; however, the data regarding MG are very limited. CASE REPORTHere, we report a patient who, during ongoing ECP therapy for his severe, refractory, chronic graft-versus-host disease (cGVHD), developed MG, although he responded very well to ECP, as indicated by the lowering of his chronic cGVHD severity grade to moderate. RESULTSDespite receiving ECP, our patient developed MG, which was resistant to treatment and required intensive care unit support. CONCLUSIONSClose surveillance is required when ECP is planned as one of the treatment alternatives in myasthenia gravis that develop in cGVHD.
dc.identifier.citationUygun, V., Daloğlu, H., Irmak Öztürkmen, S., Döşemeci, L., Karasu, G., Hazar, V. ... Yeşilipek, A. (2016). Extracorporeal photopheresis did not prevent the development of an autoimmune disease: myasthenia gravis. Transfusion, 56(12), 3081-3085. https://dx.doi.org/10.1111/trf.13821
dc.identifier.doi10.1111/trf.13821
dc.identifier.endpage3085
dc.identifier.issn0041-1132
dc.identifier.issn1537-2995
dc.identifier.issue12
dc.identifier.scopusqualityQ1
dc.identifier.startpage3081
dc.identifier.urihttps://dx.doi.org/10.1111/trf.13821
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3853
dc.identifier.volume56
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley-Blackwell
dc.relation.ispartofTransfusionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAutoimmune
dc.subjectMyasthenia Gravis (MG)
dc.subjectChronic Graft-Versus-Host Disease (cGVHD)
dc.titleExtracorporeal photopheresis did not prevent the development of an autoimmune disease: myasthenia gravis
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Hazar_Volkan.pdf
Boyut:
92.71 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu